X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2444) 2444
Publication (376) 376
Newsletter (61) 61
Newspaper Article (52) 52
Magazine Article (25) 25
Book Review (20) 20
Book Chapter (12) 12
Trade Publication Article (3) 3
Book / eBook (1) 1
Conference Proceeding (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
emtricitabine (1949) 1949
humans (1677) 1677
tenofovir (1381) 1381
index medicus (1352) 1352
hiv infections - drug therapy (985) 985
infectious diseases (985) 985
male (946) 946
female (891) 891
deoxycytidine - analogs & derivatives (829) 829
hiv (826) 826
adult (817) 817
adenine - analogs & derivatives (739) 739
anti-hiv agents - therapeutic use (656) 656
human immunodeficiency virus--hiv (582) 582
immunology (567) 567
middle aged (564) 564
anti-hiv agents - administration & dosage (514) 514
antiretroviral therapy (501) 501
deoxycytidine - therapeutic use (461) 461
pharmacology & pharmacy (445) 445
hiv infection (440) 440
drug therapy (413) 413
adenine - therapeutic use (404) 404
hiv infections - prevention & control (404) 404
drug combinations (398) 398
efavirenz (387) 387
lamivudine (380) 380
deoxycytidine - administration & dosage (379) 379
treatment outcome (375) 375
antiviral agents (374) 374
virology (369) 369
antiretroviral drugs (362) 362
organophosphonates - therapeutic use (361) 361
drug therapy, combination (355) 355
adenine - administration & dosage (350) 350
infection (344) 344
aids/hiv (323) 323
hiv infections - virology (317) 317
organophosphonates - administration & dosage (315) 315
anti-hiv agents - adverse effects (312) 312
microbiology (303) 303
hiv-1 - drug effects (299) 299
prevention (298) 298
viral load (292) 292
therapy (269) 269
health aspects (264) 264
tenofovir disoproxil fumarate (259) 259
double-blind (258) 258
young adult (234) 234
dosage and administration (233) 233
acquired immune deficiency syndrome--aids (232) 232
research (231) 231
hiv-1 (230) 230
pharmacokinetics (227) 227
highly active antiretroviral therapy (225) 225
cd4 lymphocyte count (208) 208
safety (208) 208
clinical trials (204) 204
aids (202) 202
analysis (201) 201
infections (201) 201
antiretroviral agents (194) 194
pre-exposure prophylaxis (192) 192
disoproxil fumarate (186) 186
tenofovir - therapeutic use (184) 184
men (183) 183
deoxycytidine - adverse effects (181) 181
adenine - adverse effects (178) 178
reverse transcriptase inhibitors - therapeutic use (175) 175
lamivudine - therapeutic use (173) 173
risk factors (173) 173
virus diseases (172) 172
prophylaxis (170) 170
efficacy (169) 169
article (167) 167
human immunodeficiency virus (166) 166
adolescent (165) 165
organophosphonates - adverse effects (165) 165
adherence (162) 162
drugs (162) 162
medicine, general & internal (161) 161
anti-hiv agents - pharmacology (159) 159
drug resistance, viral (158) 158
care and treatment (155) 155
adults (154) 154
emtricitabine - therapeutic use (153) 153
medicine (149) 149
ritonavir (149) 149
patients (147) 147
drug resistance (145) 145
abridged index medicus (144) 144
initial treatment (144) 144
preexposure prophylaxis (141) 141
hiv infections - complications (138) 138
hiv-1 - genetics (135) 135
risk (135) 135
anti-hiv agents - pharmacokinetics (134) 134
mutation (133) 133
drug administration schedule (130) 130
protease inhibitors (130) 130
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2502) 2502
German (30) 30
Spanish (30) 30
French (18) 18
Japanese (5) 5
Italian (4) 4
Dutch (2) 2
Chinese (1) 1
Danish (1) 1
Polish (1) 1
Russian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 12/2015, Volume 373, Issue 23, pp. 2237 - 2246
Journal Article
Clinical Infectious Diseases, ISSN 1058-4838, 08/2015, Volume 61, Issue 3, pp. 403 - 408
Journal Article
Journal Article
PLoS ONE, ISSN 1932-6203, 02/2015, Volume 10, Issue 2, p. e0116297
Background Drug choice and metabolic changes with antiretroviral therapy contribute to cardiovascular risk in persons with HIV-1 infection. Methods A... 
ABACAVIR USE | MYOCARDIAL-INFARCTION | UPDATED GUIDELINES | HIV | MULTIDISCIPLINARY SCIENCES | TENOFOVIR DF/EMTRICITABINE | ZIDOVUDINE/LAMIVUDINE | ANTIRETROVIRAL THERAPY | QUALITY-OF-LIFE | TENOFOVIR/EMTRICITABINE | ADHERENCE | HIV-1 | Lamivudine - administration & dosage | Follow-Up Studies | Cholesterol - blood | Humans | Middle Aged | Male | Tenofovir - administration & dosage | Hypercholesterolemia - drug therapy | Lamivudine - adverse effects | Adult | Female | Dideoxynucleosides - adverse effects | Emtricitabine - administration & dosage | Dideoxynucleosides - administration & dosage | HIV Infections - blood | Emtricitabine - adverse effects | Hypercholesterolemia - blood | Tenofovir - adverse effects | Benzoxazines - administration & dosage | Benzoxazines - adverse effects | HIV Infections - complications | HIV Infections - drug therapy | Hypercholesterolemia - complications | Drug Combinations | Highly active antiretroviral therapy | Antiviral agents | Hypercholesterolemia | Blood cholesterol | Low density lipoproteins | Comparative analysis | Cardiovascular diseases | HIV (Viruses) | Trans fatty acids | Emtricitabine | Lipoproteins (low density) | Antiretroviral drugs | Therapy | Health risks | Lipids | Cardiovascular disease | Lamivudine | Triglycerides | Efavirenz | Cholesterol | Antiretroviral therapy | Tenofovir | Randomization | Acquired immune deficiency syndrome--AIDS | Antiretroviral agents | Human immunodeficiency virus--HIV | Abacavir | Lipoproteins (high density) | AIDS | Acquired immune deficiency syndrome | Human immunodeficiency virus
Journal Article
Journal of Pharmaceutical and Biomedical Analysis, ISSN 0731-7085, 07/2018, Volume 156, pp. 163 - 169
A liquid chromatography with triple quadrupole mass spectrometry method was developed and validated for the determination of tenofovir and tenofovir... 
Tenofovir | Plasma | Cerebrospinal fluid | Tenofovir alafenamide | Mass spectrometry | CHEMISTRY, ANALYTICAL | LABELED INTERNAL STANDARDS | ELVITEGRAVIR | EMTRICITABINE | IMPLEMENTATION | HUMAN-IMMUNODEFICIENCY-VIRUS | TANDEM MASS-SPECTROMETRY | REVERSE-TRANSCRIPTASE INHIBITOR | PHARMACOKINETICS | PRODRUG | PHARMACOLOGY & PHARMACY | SIMULTANEOUS QUANTIFICATION | Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination - analysis | HIV Infections - blood | HIV Infections - cerebrospinal fluid | Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination - therapeutic use | Emtricitabine - therapeutic use | Reproducibility of Results | Adenine - analogs & derivatives | Tenofovir - therapeutic use | Humans | Adenine - analysis | Chromatography, High Pressure Liquid | Anti-HIV Agents - analysis | Tandem Mass Spectrometry | Adenine - therapeutic use | Emtricitabine - analysis | Tenofovir - analogs & derivatives | Quinolones - analysis | Quinolones - therapeutic use | Solid Phase Extraction | Tenofovir - analysis | Cobicistat - analysis | HIV Infections - drug therapy | Cobicistat - therapeutic use | Drug Combinations | Antiviral agents | Ionization | Analysis | Pharmacy | Formic acid | Nitriles | Liquid chromatography | Organic acids | mass spectrometry | tenofovir alafenamide | plasma | tenofovir | cerebrospinal fluid
Journal Article
Journal Article
PLoS ONE, ISSN 1932-6203, 07/2015, Volume 10, Issue 7, p. e0134430
Objective To assess, in a clinical cohort, the efficacy of switching treatment in virologically-suppressed patients to tenofovir/emtricitabine/rilpivirine as a... 
MULTIDISCIPLINARY SCIENCES | DISOPROXIL FUMARATE | EMTRICITABINE | SINGLE-TABLET REGIMEN | RILPIVIRINE | RPV/TDF/FTC | TENOFOVIR | Tenofovir - blood | Follow-Up Studies | Humans | Middle Aged | Emtricitabine, Rilpivirine, Tenofovir Drug Combination - therapeutic use | Male | Tenofovir - administration & dosage | Anti-HIV Agents - administration & dosage | Rilpivirine - therapeutic use | Rilpivirine - blood | Adult | Anti-HIV Agents - therapeutic use | Female | Anti-HIV Agents - blood | Drug Therapy, Combination | Rilpivirine - administration & dosage | Emtricitabine - administration & dosage | Emtricitabine - therapeutic use | Tenofovir - therapeutic use | Emtricitabine, Rilpivirine, Tenofovir Drug Combination - administration & dosage | Emtricitabine - blood | HIV Infections - drug therapy | Drug Substitution | Viral Load - drug effects | Drug Combinations | Virus diseases | Highly active antiretroviral therapy | Care and treatment | Protease inhibitors | Proteases | DNA polymerases | Health aspects | Emtricitabine | Antiretroviral drugs | RNA-directed DNA polymerase | Viremia | Viruses | Proteinase inhibitors | Signal monitoring | Patients | Switching | Chromatography | Antiretroviral therapy | Tenofovir | Non-nucleoside reverse transcriptase inhibitors | Acquired immune deficiency syndrome--AIDS | Antiretroviral agents | Nucleoside reverse transcriptase inhibitors | Human immunodeficiency virus--HIV | Scientific imaging | Drug therapy | Mass spectrometry | Drug dosages | Genotypes | Acquired immune deficiency syndrome | AIDS | HIV | Human immunodeficiency virus
Journal Article
Clinical Infectious Diseases, ISSN 1058-4838, 08/2015, Volume 61, Issue 4, pp. 572 - 580
Journal Article
Journal Article
PLoS ONE, ISSN 1932-6203, 11/2016, Volume 11, Issue 11, p. e0165505
The coformulation of the nucleos(t) ide analogs (NA) tenofovir (TFV) disoproxil fumarate (TDF) and emtricitabine (FTC) is approved for HIV-infection treatment... 
NUCLEOSIDE | TENOFOVIR DISOPROXIL FUMARATE | ANTIRETROVIRAL ACTIVITY | PHOSPHORYLATION | POPULATION PHARMACOKINETICS | DIPHOSPHATE | PHARMACOLOGY | MULTIDISCIPLINARY SCIENCES | EMTRICITABINE | VS. SEQUENTIAL-ANALYSIS | HIV-INFECTED ADULTS | Anti-HIV Agents - pharmacology | Deoxyadenine Nucleotides - metabolism | Tenofovir - blood | Diphosphates - metabolism | Prospective Studies | Humans | Middle Aged | Tenofovir - pharmacology | Male | Emtricitabine - pharmacology | HIV - drug effects | Young Adult | Emtricitabine - pharmacokinetics | Computer Simulation | Tenofovir - metabolism | Adult | Female | Deoxycytosine Nucleotides - metabolism | Anti-HIV Agents - blood | Anti-HIV Agents - metabolism | Emtricitabine - metabolism | Emtricitabine - blood | Tenofovir - pharmacokinetics | Polyphosphates - metabolism | Models, Biological | Anti-HIV Agents - pharmacokinetics | HIV Infections - drug therapy | DNA polymerases | Antiviral agents | Models | Health aspects | Analysis | Plasma | RNA-directed DNA polymerase | Prophylaxis | Leukocytes (mononuclear) | Infections | Tenofovir | Acquired immune deficiency syndrome--AIDS | Metabolites | Human immunodeficiency virus--HIV | Peripheral blood mononuclear cells | Drug dosages | Pharmaceutical sciences | Emtricitabine | Dosing | Antiretroviral drugs | Pharmacodynamics | Computer simulation | Nonlinear analysis | Data processing | Pharmacology | Metabolism | Deoxyadenosine | Simulation | Pharmacy | Intracellular | Pharmacokinetics | Acquired immune deficiency syndrome | AIDS | HIV | Human immunodeficiency virus
Journal Article